NCT01416311已完成不适用
Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,797
- 主要终点
- The number of subjects with any adverse events treated with REVOLADE
研究概览
简要总结
To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.
<Priority investigation item> Thromboembolism
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with chronic idiopathic thrombocytopenic purpura
排除标准
- •Not applicable
研究组 & 干预措施
Subjects prescribed REVOLADE
Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
干预措施: Eltrombopag (Drug)
结局指标
主要结局
The number of subjects with any adverse events treated with REVOLADE
时间窗: 1 year
次要结局
- Appearance of thromboembolism(1 year)
研究者
相似试验
已完成
不适用
Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)NCT02146378Pfizer500
进行中（未招募）
不适用
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal AnemiaRenal AnemiaNCT04899661Bayer1,081
已完成
不适用
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)Respiratory DisordersNCT01395862GlaxoSmithKline1,001
已完成
不适用
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)SARS-CoV-2 InfectionNCT05687877AstraZeneca366
已完成
不适用
Specified Drug Use-Results Survey of RegniteRestless Legs SyndromeNCT01887613Astellas Pharma Inc1,597